drugset / Trial / NCT06419621
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This multicenter, randomized, double-blind study will evaluate the safety and efficacy of PM8002 in combination with Nab-Paclitaxel compared with placebo combined with Nab-Paclitaxel as first-line treatment in inoperable locally advanced/metastatic triple-negative breast cancer(TNBC)
Timeline
- Start
- 2024-06-11
- Primary completion
- 2027-07
- Completion
- 2028-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pumitamig | Protein / enzyme biologic | 20 mg/kg | Intravenous |
| Background | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |